Type of nano carrier | Lipid or polymer used | Drug | Method | Particle size range (nm) | Evaluation | Results | References |
---|---|---|---|---|---|---|---|
Polymer | Chitosan sodium alginate | Betamethasone sodium phosphate | Ionotropic gelation | 168–692 | In-vivo and in-vitro studies | Better in-vivo and in-vitro skin permeation studies. | [144] |
Polymer | Chitosan | Bevacizumab | Emulsion evaporation | 88.9 ± 106.7 | In-vivo and in-vitro studies | These inhibit VEGF expression in rat retina and show a long duration of action | [145] |
Liposo mes | Cholesterol | Bevacizumab | Dehydration rehydration | 80 − 20 | In-vivo cytotoxicity and transport | When compared to non-liposomal formulations, these achieve higher concentrations in the retina. | [130] |
SLN | Cetyltrimethyl ammonium bromide | Epigallocat echin gallate | Multiple emulsion | Less than 300 | In-vivo and in-vitro release studies | There was no eye discomfort and first-order kinetic release with epigallocatechin-loaded cationic lipid nanoparticles. | [98] |
NLC | Precirol ATO 5 squalene | Triamcinolone acetonide | Homogenization | 100 to 300 | In-vivo and in-vitro | The study with Triamcinol one loaded NLC found no eye harm or discomfort. | [146] |
Polymer s | Chitosan | Curcumin | Coacervation | 61.5 to 90 | In-vivo and in-vitro studies | These were found to be nontoxic, nonirritant, and to have a better mucoadhesive action. Curcumin-loaded nanoparticles inhibited cell proliferation in the rabbit eye. | [147] |